Daclatasvir (BMS-790052)

Katalognr.S1482 Batch:S148202

Skriv ut

Tekniska data

Formel

C40H50N8O6

Molekylvikt 738.88 CAS-nr. 1009119-64-5
Löslighet (25°C)* In vitro DMSO 148 mg/mL (200.3 mM)
Ethanol 148 mg/mL (200.3 mM)
Water Insoluble
In Vivo (Tillsätt lösningsmedel till produkten individuellt och i ordning.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml betyder svårlösligt eller olösligt.
* Vänligen notera att Selleck testar lösligheten för alla förbindelser internt, och den faktiska lösligheten kan skilja sig något från publicerade värden. Detta är normalt och beror på små variationer mellan olika partier.
* Rumstempererad frakt (Stabilitetstester visar att denna produkt kan fraktas utan några kylåtgärder.)

Beredning av stamlösningar

Biologisk aktivitet

Beskrivning Daclatasvir (BMS-790052, EBP883) är en mycket selektiv hämmare av HCV NS5A med EC50 på 9-50 pM, för ett brett spektrum av HCV replikon-genotyper och JFH-1 genotyp 2a infektiöst virus i cellkultur. Fas 3.
Mål
HCV NS5A
9 pM-50 pM(EC50)
In vitro Daclatasvir (BMS-790052) is one of the most potent inhibitors of HCV replication reported so far. The mean EC50 values of this compound are 50 and 9 pM for HCV genotype 1a and 1b replicons, respectively. It displays a therapeutic index (CC50/EC50) of at least 105 and is inactive towards a panel of 10 RNA and DNA viruses, with EC50 higher than 10 μM. This confirms its specificity for HCV. In Huh7 cells harboring the HCV genotype 1b replicons, it blocks both transient and stable HCV genome replication, with EC50 values ranging from 1-15 pM. At concentrations of 100 pM or 1 nM, it has been shown to alter the subcellular localization and biochemical fractionation of NS5A. This compound inhibits hybrid replicons containing HCV genotype-4 NS5A genes with EC50 of 7-13 pM. Residue 30 of NS5A is an important site for BMS-790052-mediated resistance in the hybrid replicons.
Egenskaper Förstklassig, högselektiv hämmare av hepatit C-virus (HCV) NS5A med pikomolära EC50-värden.

Protokoll (från referens)

Kinasanalys:[4]
  • FRET-analys för HCV NS5A-hämmare

    Denna peptid (Ac-Asp-Glu-Asp [EDANS]-Glu-Glu-Abu-[COO] Ala-Ser-Lys [DABCYL]-NH2) innehåller en fluorescerande donator {EDANS, 5-[(2-aminoetyl)amino]naftalen-1-sulfonsyra} nära ena änden och en acceptor {DABCYL, 4-[(4-dimetylamino)fenyl]azo}bensoesyra} nära den andra. Intermolekylär resonansenergiöverföring mellan donatorn och acceptorn släcker peptidens fluorescens, men när NS3 Proteases klyver peptiden frigörs produkterna från resonansenergiöverföringssläckningen. Allt eftersom mer substrat klyvs av NS3 Proteases ökar donatorns fluorescens med tiden. Detektionsreagenserna är: 5× luciferas-cellodlingslyseringsreagens utspätt med dH2O till 1×, med tillsats av NaCl (150 mM) och FRET-peptid (20 μM). HCV-Huh-7-celler placerades i 96-brunnsplattor och fick fästa över natten (1×104 celler per brunn). Nästa dag tillsattes Daclatasvir (BMS-790052) till brunnarna och plattan inkuberades i 72 timmar. Plattorna sköljdes sedan med PBS och FRET-detektion utfördes genom tillsats av 30 μL av ovanstående FRET-peptiddetektionsreagenser per brunn. Signaler samlades in med hjälp av ett Cytofluor 4000-instrument, inställt på 340 nm (excitation) / 490 nm (emission) i automatiskt läge, kördes i 20 cykler eller mindre, och plattan lästes av i kinetiskt läge. Efter FRET-detektion tillsattes 40 μL luciferassubstrat till varje brunn och luciferasaktiviteten mättes.

Cellanalys:[1]
  • Cellinjer

    HCV replicon cells (Huh7)

  • Koncentrationer

    0.1 pM - 50 μM, dissolved in DMSO (the final concentration of DMSO is 0.5%)

  • Inkubationstid

    72 hours

  • Metod

    Daclatasvir (BMS-790052) is added to 96-well plates containing HCV replicon cells seeded approximately 12 hours before in 200 µL media. The cell plates are tested for replication activity and cytotoxicity after 72 hours of incubation. Cytotoxicity is measured with CellTiter-Blue, after which the media and dye are removed, plates are inverted and the remaining liquid is blotted with paper towels. Replication activity of the HCV genotype 1a cell lines is quantified using Renilla luciferase. 1× Renilla luciferase lysis buffer (30 µL) is added to each well and plates are incubated with gentle shaking for 15 min. Renilla luciferase substrate (40 µL) is then added and the signals are detected using a Top Count luminometer set for light emission quantification. One hundred per cent activity is calculated for each cell line for the DMSO-only wells; percentage activity is calculated for each concentration of the inhibitor by dividing the average value for wells containing this compound by the average value for wells containing DMSO.

Referenser

  • https://pubmed.ncbi.nlm.nih.gov/20410884/
  • https://pubmed.ncbi.nlm.nih.gov/21513964/
  • https://pubmed.ncbi.nlm.nih.gov/22203595/
  • https://pubmed.ncbi.nlm.nih.gov/15793110/

Kundvalidering av produkt

<p>The toxicity of BMS-790052 (BMS) and Telaprevir (TPV) was measured by seeding 96-well plates to 70% confluence and exposing the cells to up to 50 μM of compound for 72 hours. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was added to each well at a final concentration of 500 μg/ml 4 h before dissolving crystals in 100 μl of DMSO and measuring at 550 nm UV wavelengths. The 50% cytotoxic concentration (CC50) was then calculation using the OD550 value and the following formula: log CC50=log concentration of HPP-[(HPP-50)/(HPP-LPP)×log d HPP: highest protective percentage closest to 50% LPP: Lowest protective percentage closest to 50% d: dilution factor</p>

, 2011 , Dr. Julie Sheldon,Dr Esteban Domingo and Dr Celia Perales

<p>Huh7.5 cells were infected with JFH-1 (2a) strain. Once the cells reached 80% infectivity they were treated with pMconcentration of BMS790052 for two different time points. Cells were collected in SDS sample loading buffer and probed for NS5A and GAPDH. After 16hrs hyperphosphorylated NS5A disappeared with increasing concentration of the drug. 40hrs of treatment resulted complete disappearance of NS5A. GAPDH is internal control.</p><div><div> </div></div><p> </p>

, 2011 , Dr. Anita Nag of Florida State University

<p>80% infected HCV JFH-1 cells were treated with several concentrations of BMS790052 in pMrange. Cells were fixed after 16hrs and NS5A was probed.Cells treated with BMS790052 shows NS5A present in clusters compared to an even cytoplasmic distribution in untreated cells.</p>

, 2011 , Dr. Anita Nag of Florida State University

Sensitivity of PR63cc to the combinatory treatment with asunaprevir and daclatasvir. Huh7.5.1 cells infected with PR63cc or JFH1 at an MOI of 0.05 for 3 days were treated with either asunaprevir, daclatasvir or in combination for another 3 days. 40 nM asunaprevir and 0.05 nM daclatasvir, approximately the EC50 concentration of the each inhibitor for JFH1, were used. The antiviral efficiency of each compound was evaluated by quantifying the intracellular HCV RNA by RT-qPCR. Data were expressed as the percentage of mock treatment control. The error bars were calculated from two independent experiments. ns, P > 0.05. *, P < 0.05.

Data från [ , , Antiviral Res, 2017, 139:18-24 ]

Sellecks Daclatasvir (BMS-790052) Har citerats av 61 Publikationer

Rapid hepatitis C virus replication machinery removal after antiviral treatment with DAA monitored by multimodal imaging [ Structure, 2025, S0969-2126(25)00193-5] PubMed: 40553718
Hepatitis C virus-induced differential transcriptional traits in host cells after persistent infection elimination by direct-acting antivirals in cell culture [ J Med Virol, 2024, 96(7):e29787] PubMed: 38988177
Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa [ EMBO Mol Med, 2024, 16(4):870-884] PubMed: 38462666
Patient-derived rhabdomyosarcoma cells recapitulate the genetic and transcriptomic landscapes of primary tumors [ iScience, 2024, 27(10):110862] PubMed: 39319271
Unraveling the dynamics of hepatitis C virus adaptive mutations and their impact on antiviral responses in primary human hepatocytes [ J Virol, 2024, e0192123.] PubMed: 38319104
Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus [ Viruses, 2023, 15(4)981] PubMed: 37112961
Hepatitis C virus cell culture adaptive mutations enhance cell culture propagation by multiple mechanisms but boost antiviral responses in primary human hepatocytes [ bioRxiv, 2023, 2023.11.22.568224] PubMed: 38045248
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture [ Commun Biol, 2022, 5(1):154] PubMed: 35194144
Going Viral: An Investigation into the Chameleonic Behaviour of Antiviral Compounds [ Chemistry, 2022, e202202798.] PubMed: 36286339
A Novel Drug to Induce Apoptosis in Advanced Prostate Cancer Cells [ STARS, 2022, 1202] PubMed: NONE

RETURPOLICY
Selleck Chemicals villkorslösa returpolicy säkerställer en smidig online-shoppingupplevelse för våra kunder. Om du på något sätt är missnöjd med ditt köp kan du returnera artikeln/artiklarna inom 7 dagar efter mottagandet. I händelse av produktkvalitetsproblem, antingen protokollrelaterade eller produktrelaterade problem, kan du returnera artikeln/artiklarna inom 365 dagar från det ursprungliga köpdatumet. Vänligen följ instruktionerna nedan vid retur av produkter.

FRAKT OCH FÖRVARING
Sellecks produkter transporteras i rumstemperatur. Om du tar emot produkten i rumstemperatur kan du vara trygg; Sellecks kvalitetskontrollavdelning har utfört experiment för att verifiera att placering i normal temperatur under en månad inte påverkar den biologiska aktiviteten hos pulverprodukter. Efter insamling ska produkten förvaras i enlighet med de krav som beskrivs i databladet. De flesta av Sellecks produkter är stabila under de rekommenderade förhållandena.

EJ AVSEDD FÖR ANVÄNDNING PÅ MÄNNISKOR, INOM VETERINÄRDIAGNOSTIK ELLER FÖR TERAPEUTISKT BRUK.